Characterization of a novel POLD1 missense founder mutation in a Spanish population
Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10045/66512
Título: | Characterization of a novel POLD1 missense founder mutation in a Spanish population |
---|---|
Autor/es: | Ferrer‐Avargues, Rosario | Díez‐Obrero, Virginia | Martín‐Tomás, Ester | Hernández Illán, Eva | Castillejo, María Isabel | Codoñer‐Alejos, Alan | Barberá, Víctor Manuel | Sánchez-Heras, Ana Beatriz | Segura, Ángel | Juan, María-Jose | Tena, Isabel | Castillejo, Adela | Soto, José Luis |
Grupo/s de investigación o GITE: | Biotecnología | Transducción de Señales en Bacterias |
Centro, Departamento o Servicio: | Universidad de Alicante. Departamento de Biotecnología | Universidad de Alicante. Departamento de Fisiología, Genética y Microbiología |
Palabras clave: | Colon/rectal cancer | Molecular genetics |
Área/s de conocimiento: | Biología Celular | Genética |
Fecha de publicación: | abr-2017 |
Editor: | John Wiley & Sons |
Cita bibliográfica: | Journal of Gene Medicine. 2017, 19(4): e2951. doi:10.1002/jgm.2951 |
Resumen: | Background: We identified a new and a recurrent POLD1 mutation associated with predisposition to colorectal cancer (CRC). We characterized the molecular and clinical nature of the potential POLD1 founder mutation in families from Valencia (Spain). Methods: Clinical and molecular data were collected from four independent families known to have a POLD1 Leu474Pro mutation. To establish its founder effect, haplotype construction was performed using 14 flanking POLD1 polymorphic markers. We calculated penetrance estimates and clinical expressivity, globally and stratified by age and sex. Results: We included 32 individuals from the four families: 20 carriers and 12 noncarriers. A common haplotype was identified in these families in a region comprising 2,995 Mb, confirming L474P as the first founder POLD1 mutation identified. Thirteen tumors diagnosed in 10 POLD1 carriers: eight CRC, three endometrial and two other tumors were considered. The median age of cancer onset for POLD1 mutation carriers was 48 years. The observed penetrance was 50% and the cumulative risk at age of 50 years was 30%. Conclusions: The findings of the present study contribute to a better understanding of CRC genetics in the Spanish population. The clinical phenotype for this mutation is similar to that in Lynch syndrome. Future studies using next generation sequencing with large gene panels for any hereditary cancer condition will offer the possibility of detecting POLE/POLD1 mutations in unsuspected clinical situations, demonstrating a more real and unbiased picture of the associated phenotype. |
Patrocinador/es: | This work was supported by the Institute for Health and Biomedical Research of Alicante (ISABIAL, UGP‐16‐146). RFA is recipient of a Fellowship from the Consellería Educación of the Valencian Community. ACA is funded by the Acción Juvenil from the Spanish Ministry of Economy and Competitiveness. VDO is recipient of a Fellowship from the Spanish Association Against Cancer (AECC). AC and MIC are funded by Health and Biomedical Research Foundation from the Valencian Region (FISABIO). EHI is recipient of a fellowship from the Fondo Investigación Sanitaria ISCIII (FI12/00233). |
URI: | http://hdl.handle.net/10045/66512 |
ISSN: | 1099-498X (Print) | 1521-2254 (Online) |
DOI: | 10.1002/jgm.2951 |
Idioma: | eng |
Tipo: | info:eu-repo/semantics/article |
Derechos: | © 2017 John Wiley & Sons, Ltd. |
Revisión científica: | si |
Versión del editor: | http://dx.doi.org/10.1002/jgm.2951 |
Aparece en las colecciones: | INV - GIDBT - Artículos de Revistas INV - TSB - Artículos de Revistas |
Archivos en este ítem:
Archivo | Descripción | Tamaño | Formato | |
---|---|---|---|---|
2017_Ferrer-Avargues_etal_JGeneMed_final.pdf | Versión final (acceso restringido) | 202,24 kB | Adobe PDF | Abrir Solicitar una copia |
2017_Ferrer-Avargues_etal_JGeneMed_accepted.pdf | Accepted Manuscript (acceso abierto) | 552,88 kB | Adobe PDF | Abrir Vista previa |
Todos los documentos en RUA están protegidos por derechos de autor. Algunos derechos reservados.